EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Challenges in the identification and quantification of an unknown impurity in chenodeoxycholic acid drug substance

Natalja Bouwhuis, Yasmin Polak, Anneliene M Schimmel, Yuma A Bijleveld, Martin A Giera, Marieke Heijink, Frédéric M Vaz, Albert H Bootsma, Laureen A Ten Berg-Lammers, Noortje E L Swart, Carla E M Hollak, Bart A W Jacobs und 1 weitere

European Journal of Pharmaceutical Sciences · 2025

DOI: 10.1016/j.ejps.2024.106979 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutical Sciences, 2025. Verfasst von Natalja Bouwhuis und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Clinical Pharmacology, Amsterdam UMC, Meibergdreef 9 1105 AZ, Amsterdam, The Netherlands; Platform Medicine for Society, A…. Hauptthemen laut MEDLINE: Chenodeoxycholic Acid, Drug Contamination. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2018 the Amsterdam University Medical Centre decided to prepare chenodeoxycholic acid (CDCA) capsules (also known as pharmacy compounding) for patients with the genetic metabolic disease cerebrotendinous xanthomatosis (CTX) when the product with a marketing authorization was commercially unavailable for patients. However, after reanalysis, unknown impurities were identified in the CDCA active pharmaceutical ingredient (API) using thin-layer chromatography from the European Pharmacopoeia (Ph.Eur.) monograph. Therefore, the API did not comply with the Ph.Eur. specifications for related substances and as a result, pharmacy compounding was halted and an investigation was initiated to identify and quantify the unknown impurities. Meanwhile, a second CDCA API was sourced from another manufacturer. However, this API also appeared to contain an unknown impurity. This impurity could be identified as a dimer of CDCA using reversed phase liquid chromatography mass spectrometry. Since the Ph.Eur. at the time did not describe a suitable analytical method for the quantification of this new impurity, a high pressure liquid chromatography with differential refractometer (HPLC-RI) method was developed to quantify the dimer. Subsequently, in 2019, a new draft version of the CDCA Ph.Eur. monograph was published, including the dimer as a new impurity together with a HPLC-RI method for its identification and quantification. The CDCA-dimer is classified as non-toxic and permitted in the CDCA API up to a maximum of 0.5 %. Because the API complied with the updated Ph.Eur. specifications, pharmacy compounding of CDCA capsules could be resumed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chenodeoxycholic AcidDrug ContaminationChromatography, High Pressure LiquidDrug CompoundingHumansCapsulesChromatography, Thin LayerMass SpectrometryXanthomatosis, Cerebrotendinous

Stichwörter der Autor:innen

Cerebrotendinous xanthomatosisChenodeoxycholic acidPharmacy compoundingPharmacy preparationsQuality controlRelated substances

Substanzen

Chenodeoxycholic AcidCapsules

Autor:innen und Institutionen

  • Department of Pharmacy and Clinical Pharmacology, Amsterdam UMC, Meibergdreef 9 1105 AZ, Amsterdam, The Netherlands; Platform Medicine for Society, Amsterdam UMC, Meibergdreef 9 1105 AZ, Amsterdam, The Netherlands. Elec…
  • Department of Pharmacy and Clinical Pharmacology, Amsterdam UMC, Meibergdreef 9 1105 AZ, Amsterdam, The Netherlands; Platform Medicine for Society, Amsterdam UMC, Meibergdreef 9 1105 AZ, Amsterdam, The Netherlands.
  • Department of Pharmacy and Clinical Pharmacology, Amsterdam UMC, Meibergdreef 9 1105 AZ, Amsterdam, The Netherlands.
  • Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2 2333 ZA, Leiden, The Netherlands.
  • Department of Clinical Chemistry and Pediatrics, Laboratory Genetic Metabolic Diseases, Emma Children's Hospital, Amsterdam UMC, Meibergdreef 9 1105 AZ, Amsterdam, The Netherlands; Amsterdam Gastroenterology Endocrinolo…
  • Department of Clinical Chemistry and Pediatrics, Laboratory Genetic Metabolic Diseases, Emma Children's Hospital, Amsterdam UMC, Meibergdreef 9 1105 AZ, Amsterdam, The Netherlands.

Zitieren

APA

Bouwhuis, N., Polak, Y., Schimmel, A. M., Bijleveld, Y. A., Giera, M. A., Heijink, M., Vaz, F. M., Bootsma, A. H., Berg-Lammers, L. A. T., Swart, N. E. L., Hollak, C. E. M., Jacobs, B. A. W., & Kemper, E. M. (2025). Challenges in the identification and quantification of an unknown impurity in chenodeoxycholic acid drug substance. European Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.ejps.2024.106979

Vancouver

Bouwhuis N, Polak Y, Schimmel AM, Bijleveld YA, Giera MA, Heijink M, et al. Challenges in the identification and quantification of an unknown impurity in chenodeoxycholic acid drug substance. European Journal of Pharmaceutical Sciences. 2025. doi:10.1016/j.ejps.2024.106979

BibTeX
@article{Bouwhuis2025,
  author = {Bouwhuis, Natalja and Polak, Yasmin and Schimmel, Anneliene M and Bijleveld, Yuma A and Giera, Martin A and Heijink, Marieke and Vaz, Frédéric M and Bootsma, Albert H and Berg-Lammers, Laureen A Ten and Swart, Noortje E L and Hollak, Carla E M and Jacobs, Bart A W and Kemper, E Marleen},
  title = {Challenges in the identification and quantification of an unknown impurity in chenodeoxycholic acid drug substance},
  journal = {European Journal of Pharmaceutical Sciences},
  year = {2025},
  doi = {10.1016/j.ejps.2024.106979}
}
Kostenlos starten →